TNFSF10 and prostate carcinoma: In addition, a combination approach of SFN with TRAIL synergistically eliminate prostate cancer stem-like cells in vitro by attenuating TRAIL-induced NF-κB binding and downregulating markers like C-X-C chemokine receptor type 4 (CXCR-4), jagged1, sex determining region Y-box 2, Notch 1, and Nanog [121].